Elevance Health Shares Drop 7% As 2026 Outlook Disappoints

Elevance reported Q4 2025 revenue of $49.3 billion (+10% YoY) driven by higher premium yields, acquisitions and Medicare Advantage growth, with Q4 GAAP diluted EPS $2.47 (vs. $1.81) and adjusted EPS $3.33 (vs. $3.23). Full-year revenue was $197.6 billion (+13%) while full-year GAAP EPS fell to $25.21 and adjusted EPS declined to $30.29; benefit expense ratios widened (Q4 93.5%, FY 90.0%) and medical membership slipped to ~45.2M. Management guided down for 2026 (GAAP EPS at least $22.30; adjusted at least $25.50; low-single-digit revenue decline), declared a $1.72 Q1 dividend, and the stock has already moved sharply lower on the outlook and margin pressures.

Analysis

Market structure: ELV’s guidance implies durable margin pressure (benefit ratio +150 bps y/y to 90% for 2025) and revenue down low-single digits in 2026, which directly benefits larger diversified payers (e.g., UNH) and specialty PBMs that can extract pricing or network leverage; ACA-heavy cohorts and regional Medicaid-focused plans are losers. Higher medical cost trends and Medicare Part D dynamics indicate pricing power is shifting to incumbents with scale; membership down 1% (45.2M) signals demand sensitivity to pricing and product mix changes. Cross-asset: expect ELV equity volatility to stay elevated (implied vol +20-40% vs peers near-term), corporate credit spreads to widen modestly (20–60 bps), and modest negative correlation with long-duration Treasuries as growth/earnings risk re-rates.

Risk assessment: tail risks include regulatory shocks (Medicare/ACA reimbursement changes or new drug-pricing mandates) and a severe Part D reimbursement shock that could cost multiple dollars of EPS; operational risk from M&A integration could further depress earnings in 2026. Time horizons: immediate (days) — elevated IV and liquidity-driven repricing; short-term (weeks–months) — Q1 dividend, CMS/plan transfer data and 1Q26 results will re-rate guidance; long-term (2027+) — management’s target of >=12% adjusted EPS growth depends on disciplined pricing and membership stabilization. Hidden dependencies include PBM passthroughs and risk-adjustment flows; catalysts: CMS enrollment windows, drug-pricing legislation, 1Q26 call (Mar–May).

Trade implications: direct plays — establish a tactical 1–2% short in ELV equity (or equivalent via 3-month put spread) to capture near-term downside to $260–$290 if guidance disappoints further; pair trade — long UNH (1–2%) vs short ELV (1%) to capture relative operating leverage and scale advantages. Options — buy 3-month put spreads on ELV with strikes ~10%/20% OTM to limit capital and sell 6–9 month OTM calls (iron-condor for income if implied vol normalizes). Sector rotation — trim mid-cap managed-care exposure, reallocate to large-cap diversified payers and risk-bearing tech-enabled care managers. Entry/exit — enter short/puts while IV > 30% and target exits on IV compression or price hitting $260 (stop-loss $330 on short).

Contrarian angles: consensus may overshoot downside — management’s reaffirmed long-term algorithm and a $1.72 Q1 dividend create a valuation floor; if ELV trades below $300 with credit spreads stabilizing, a 12–18 month recovery trade (buy Jan 2027 call or outright equity) could produce asymmetric upside. Historically, managed-care selloffs tied to one-year cost spikes have reversed when pricing resets and risk-adjustment normalizes; watch membership stabilization (no further y/y decline after two quarters) and Part D margin stabilization as triggers. Unintended consequences — aggressive short positioning risks snap-back if management executes targeted rate actions or M&A synergies materialize faster than modeled.

Key Decisions for Investors

• Establish a tactical 1–2% short position in ELV equity (or equivalent via a 3-month put spread) while implied volatility >30%; size to risk no more than 0.5% portfolio loss if ELV rallies to $330; target profit zone $260–$290 within 3–6 months.
• Construct a pair trade: long 1–2% UNH vs short 1% ELV to capture relative share/scale advantage; rebalance after 6 months or if UNH/ELV spread moves >15% from entry.
• Buy a defined-risk options hedge: purchase 3-month ELV 10%/20% OTM put spread (debit) sized to cover downside of core healthcare exposure; sell 6–9 month ELV 30% OTM calls (credit) only if IV > 35% to finance premium.
• If ELV falls below $300 and credit spreads stabilize (5yr CDS move < +40bps from today), initiate a 1–1.5% long recovery position (equity or Jan 2027 calls) targeting $380 in 12–18 months; hard stop at $250.
• Reduce cyclically exposed regional/ACA-heavy managed-care exposure by 2–4% and rotate into large-cap diversified payers and specialty PBM/benefit managers over the next 30–90 days; increase cash/hedge if CMS enrollment or drug-pricing headlines turn adverse.